Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Germany Companies

Video: BioNTech's Marett On Sanofi Deal And Immunotherapy

This article was originally published in Scrip

In this video interview BioNTech chief operating officer, Sean Marett, discusses his company's recent Sanofi immunotherapy deal with Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany. They chat about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies.

Look out for more BIO-Europe exclusive interviews all this week on Scrip. To see more video interviews and panel discussions from BIO-Europe 2015 right now visit Partnering360.

Table

View full table

Related Content

Scrip

Topics

Tags:
Germany Companies
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC030314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By